Alivus Life Sciences Limited

rs,

anuary 23, 2025 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

26.6%

rder to build a sustainable business over the long term.” ( I N ₹ M I L L I ON S ) 6,418 REVENUE 26.6% QoQ 12.0% YoY ( I N ₹ M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S

12.0%

ild a sustainable business over the long term.” ( I N ₹ M I L L I ON S ) 6,418 REVENUE 26.6% QoQ 12.0% YoY ( I N ₹ M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S ) 1,370 PA

40.5%

I N ₹ M I L L I ON S ) 6,418 REVENUE 26.6% QoQ 12.0% YoY ( I N ₹ M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S ) 1,370 PAT 43.7% QoQ 15.3% YoY GPL: Glenmark Pharmaceuti

15.2%

L L I ON S ) 6,418 REVENUE 26.6% QoQ 12.0% YoY ( I N ₹ M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S ) 1,370 PAT 43.7% QoQ 15.3% YoY GPL: Glenmark Pharmaceuticals Ltd.

43.7%

Y ( I N ₹ M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S ) 1,370 PAT 43.7% QoQ 15.3% YoY GPL: Glenmark Pharmaceuticals Ltd. • Alivus registered a revenue from operations o

15.3%

M I L L I ON S ) 2,008 EBITDA 40.5% QoQ 15.2% YoY ( I N ₹ M I L L I ON S ) 1,370 PAT 43.7% QoQ 15.3% YoY GPL: Glenmark Pharmaceuticals Ltd. • Alivus registered a revenue from operations of ₹ 6,418 M

₹ 6,418

oQ 15.3% YoY GPL: Glenmark Pharmaceuticals Ltd. • Alivus registered a revenue from operations of ₹ 6,418 Mn for Q3FY25, recording a strong growth of 26.6% QoQ and 12.0% YoY. • EBITDA margins for the qua

31.3%

, recording a strong growth of 26.6% QoQ and 12.0% YoY. • EBITDA margins for the quarter were at 31.3% up 310 bps QoQ and 90 bps YoY, driven by better product mix with stable expenses. • Generic busi

310 bps

ng a strong growth of 26.6% QoQ and 12.0% YoY. • EBITDA margins for the quarter were at 31.3% up 310 bps QoQ and 90 bps YoY, driven by better product mix with stable expenses. • Generic business grew b

90 bps

owth of 26.6% QoQ and 12.0% YoY. • EBITDA margins for the quarter were at 31.3% up 310 bps QoQ and 90 bps YoY, driven by better product mix with stable expenses. • Generic business grew by 16.9% YoY and

16.9%

oQ and 90 bps YoY, driven by better product mix with stable expenses. • Generic business grew by 16.9% YoY and 25.9% QoQ to ₹ 5,966 Mn, whereas CDMO business grew by 25.0% QoQ to ₹ 300 Mn. • Non-GPL

“4th Floor, OIA House, 470, Cardinal Gracious Road Andheri (E), Mumbai 400 099, Maharashtra, India Plot No 170-172, Chandramouli Industrial Estate Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com Investor Presentation Q3 & 9M FY25 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation.”

“4 Q3 & 9M FY25 Performance Revenue (In ₹ Mill i on s ) , 5 7 2 8 , 5 3 6 6 , 5 8 8 6 , 5 0 6 9 , 6 4 1 8 EBITDA (In ₹ Mill i on s ) 30.4% 26.9% 28.0% PAT (In ₹ Mill i on s ) 31.3% 28.2% 20.7% 18.9% 18.8% 18.3% , 1 7 4 2 , 1 6 5 0 , 1 4 4 6 , 1 4 2 9 , 2 0 0 8 , 1 1 8 8 , 1 1 1 5 9 7 9 9 5 3 EPS (In ₹) .”

“FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 8 Business Performance Review 9 9 Segmental Performance | Generic API vs CDMO Generic API (Revenu e In ₹ Milli o ns ) 5,105 4,846 5,354 4,739 CDMO (Revenu e In ₹ Milli o n s ) 425 5,966 355 354 300 240 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 • Generic API revenues in Q3FY25 grew by 25.9% QoQ and 16.9% YoY.”

“• CDMO business witnessed growth of 25% QoQ, driven by demand contribution from the 4th project.”

“5% • 5th project is expected to be commercialized by H1FY26.”

“10 Segmental Performance | GPL vs Non-GPL GPL (In ₹ Mill i on s ) 31.1% 1,667 26.9% 1,541 % of Total Revenue 33.4% 37.2% 1,963 1,888 27.6% 1,773 Non-GPL (In ₹ Mill i on s ) 73.1% 4,187 68.9% 3,699 66.6% 3,923 % of Total Revenue 72.4% 4,645 3,181 62.8% Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 • In Q3FY25, GPL business witnessed a growth of 15.1% YoY and a de-growth of 6.1% QoQ.”

Registered Office

1

REGISTERED OFFICE

1

Registered Office

4th Floor, OIA House, 470, Cardinal Gracious Road Andheri (E), Mumbai 400 099, Maharashtra, India Plot No 170-172, Chandramouli Industrial Estate Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com Investor Presentation Q3 & 9M FY25 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. Thes

REGISTERED OFFICE

T: 91 22 68297979 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. CIN: L74900PN2011PLC139963 Website: www.alivus.com 20